FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922013458> ?p ?o ?g. }

• W2922013458 abstract "The efficacy of a single application of a new topical formulation containing selamectin plus sarolaner (Revolution® Plus / Stronghold® Plus, Zoetis) was evaluated against fleas and ticks infesting cats enrolled as veterinary patients in two field studies conducted in Japan and against Haemaphysalis longicornis ticks on cats in a laboratory study. In the laboratory study, sixteen cats were ranked based on pre-treatment tick counts and allocated randomly to treatment on Day 0 with either selamectin plus sarolaner or placebo. Cats were infested with adult H. longicornis on Days -2, 5, 12, 19, 26 and 33. Efficacy relative to placebo was based on live attached tick counts conducted 48 h after treatment and subsequent re-infestations. Selamectin plus sarolaner reduced live, attached H. longicornis counts by 96.4% within 48 h of treatment, and by ≥91.7% within 48 h of weekly re-infestation for 35 days, based on arithmetic means. In the field studies, 67 client-owned cats harboring six or more live fleas and 63 cats harboring four or more live attached ticks were enrolled to evaluate selamectin plus sarolaner for efficacy and safety compared with a registered product. Cats were allocated randomly to treatment with selamectin plus sarolaner or fipronil plus (S)-methoprene based on order of presentation. Treatment was administered once on Day 0 and efficacy was assessed by parasite counts conducted on Days 14 and 30 compared to the pre-treatment count. In the flea field study, live flea counts on Days 14 and 30 were reduced by 99.5% and 99.9% in the selamectin plus sarolaner group, and by 97.6% and 98.6% in the fipronil plus (S)-methoprene group, based on least squares mean percentage reductions. Clinical signs typically associated with flea allergy dermatitis improved following treatment. In the tick field study, live tick counts on Days 14 and 30 were reduced by 97.5% and 97.7% in the selamectin plus sarolaner group, and by 91.5% and 93.4% in the fipronil plus (S)-methoprene group, based on least squares mean percentage reductions. Selamectin plus sarolaner was determined to be non-inferior to fipronil plus (S)-methoprene in both field studies. There were no treatment-related adverse events in any study. A single topical dose of Revolution® Plus / Stronghold® Plus providing a minimum dosage of 6.0 mg/kg selamectin and 1.0 mg/kg sarolaner was confirmed to be effective against H. longicornis ticks on cats for one month and safe and effective in the treatment of fleas and ticks on cats enrolled as veterinary patients in Japan." @default.
• W2922013458 created "2019-03-22" @default.
• W2922013458 creator A5010714149 @default.
• W2922013458 creator A5013177432 @default.
• W2922013458 creator A5017185650 @default.
• W2922013458 creator A5038805034 @default.
• W2922013458 creator A5041072346 @default.
• W2922013458 creator A5083174288 @default.
• W2922013458 date "2019-06-01" @default.
• W2922013458 modified "2023-09-26" @default.
• W2922013458 title "Efficacy of a new topical formulation of selamectin plus sarolaner for the control of fleas and ticks infesting cats in Japan" @default.
• W2922013458 cites W1964484913 @default.
• W2922013458 cites W1968964645 @default.
• W2922013458 cites W2007427015 @default.
• W2922013458 cites W2018540177 @default.
• W2922013458 cites W2020054957 @default.
• W2922013458 cites W2028033007 @default.
• W2922013458 cites W2029663107 @default.
• W2922013458 cites W2031668484 @default.
• W2922013458 cites W2035238932 @default.
• W2922013458 cites W2076575004 @default.
• W2922013458 cites W2108667965 @default.
• W2922013458 cites W2111191227 @default.
• W2922013458 cites W2162707421 @default.
• W2922013458 cites W2286412702 @default.
• W2922013458 cites W2416589918 @default.
• W2922013458 cites W2418219898 @default.
• W2922013458 cites W2515733418 @default.
• W2922013458 cites W2604224324 @default.
• W2922013458 cites W2605048950 @default.
• W2922013458 cites W2605056555 @default.
• W2922013458 cites W2765570266 @default.
• W2922013458 cites W2794140015 @default.
• W2922013458 cites W2809509303 @default.
• W2922013458 cites W2901234874 @default.
• W2922013458 cites W2901599396 @default.
• W2922013458 cites W2903512659 @default.
• W2922013458 cites W2940409738 @default.
• W2922013458 doi "https://doi.org/10.1016/j.vetpar.2019.01.008" @default.
• W2922013458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30914264" @default.
• W2922013458 hasPublicationYear "2019" @default.
• W2922013458 type Work @default.
• W2922013458 sameAs 2922013458 @default.
• W2922013458 citedByCount "6" @default.
• W2922013458 countsByYear W29220134582019 @default.
• W2922013458 countsByYear W29220134582020 @default.
• W2922013458 countsByYear W29220134582022 @default.
• W2922013458 crossrefType "journal-article" @default.
• W2922013458 hasAuthorship W2922013458A5010714149 @default.
• W2922013458 hasAuthorship W2922013458A5013177432 @default.
• W2922013458 hasAuthorship W2922013458A5017185650 @default.
• W2922013458 hasAuthorship W2922013458A5038805034 @default.
• W2922013458 hasAuthorship W2922013458A5041072346 @default.
• W2922013458 hasAuthorship W2922013458A5083174288 @default.
• W2922013458 hasBestOaLocation W29220134581 @default.
• W2922013458 hasConcept C126322002 @default.
• W2922013458 hasConcept C140793950 @default.
• W2922013458 hasConcept C161176658 @default.
• W2922013458 hasConcept C18903297 @default.
• W2922013458 hasConcept C2776127032 @default.
• W2922013458 hasConcept C2777095047 @default.
• W2922013458 hasConcept C2777786777 @default.
• W2922013458 hasConcept C2779420972 @default.
• W2922013458 hasConcept C2779620486 @default.
• W2922013458 hasConcept C2779904517 @default.
• W2922013458 hasConcept C33070731 @default.
• W2922013458 hasConcept C42972112 @default.
• W2922013458 hasConcept C71924100 @default.
• W2922013458 hasConcept C74714110 @default.
• W2922013458 hasConcept C86803240 @default.
• W2922013458 hasConceptScore W2922013458C126322002 @default.
• W2922013458 hasConceptScore W2922013458C140793950 @default.
• W2922013458 hasConceptScore W2922013458C161176658 @default.
• W2922013458 hasConceptScore W2922013458C18903297 @default.
• W2922013458 hasConceptScore W2922013458C2776127032 @default.
• W2922013458 hasConceptScore W2922013458C2777095047 @default.
• W2922013458 hasConceptScore W2922013458C2777786777 @default.
• W2922013458 hasConceptScore W2922013458C2779420972 @default.
• W2922013458 hasConceptScore W2922013458C2779620486 @default.
• W2922013458 hasConceptScore W2922013458C2779904517 @default.
• W2922013458 hasConceptScore W2922013458C33070731 @default.
• W2922013458 hasConceptScore W2922013458C42972112 @default.
• W2922013458 hasConceptScore W2922013458C71924100 @default.
• W2922013458 hasConceptScore W2922013458C74714110 @default.
• W2922013458 hasConceptScore W2922013458C86803240 @default.
• W2922013458 hasFunder F4320313885 @default.
• W2922013458 hasLocation W29220134581 @default.
• W2922013458 hasLocation W29220134582 @default.
• W2922013458 hasOpenAccess W2922013458 @default.
• W2922013458 hasPrimaryLocation W29220134581 @default.
• W2922013458 hasRelatedWork W179676187 @default.
• W2922013458 hasRelatedWork W1987925171 @default.
• W2922013458 hasRelatedWork W2015511980 @default.
• W2922013458 hasRelatedWork W2022404481 @default.
• W2922013458 hasRelatedWork W2043899373 @default.
• W2922013458 hasRelatedWork W2062717633 @default.
• W2922013458 hasRelatedWork W2087438934 @default.
• W2922013458 hasRelatedWork W2109767095 @default.
• W2922013458 hasRelatedWork W2626174563 @default.
• W2922013458 hasRelatedWork W2922013458 @default.

• next